What is the main business of LAB Technology?

The main business activity of LAB Technology focuses on manufacture of basic pharmaceutical products.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on April 30, 2020.

Where is the headquarters located?

The headquarters is located at: ul. 3 Maja 13, 35-060 Rzeszów.

What is the share capital?

The share capital of the company is PLN 10,000 (approx. $2,701).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What revenue was generated?

The company reported a revenue of $1,253 in 2024, which is a decrease of 66.7% compared to 2023.

No, the company recorded a net loss of $554 in 2024.

What is the largest operating cost?

The largest operating cost category falls under external services. This category amounted to $1,508 in 2024, representing 83% of all operating expenses.

LAB Technologysp. z o.o.

Manufacture of basic pharmaceutical products

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2020-04-30

Share capital

10,000.00 PLN

Registered address

ul. 3 Maja 13/Piętro 3, 35-060 Rzeszów, Poland

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 5 of 5 financial statements were filed late (the longest delay 829 days for 2020).

2025not filed
202430/07/2026
202330/07/2026
202204/07/2024
202103/07/2024
202022/01/2024

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue

This companyUSD 1.25kMedianUSD 165.97kAverageUSD 2.30m

Net profit

This companyUSD -554.01MedianUSD 1.32kAverageUSD 109.80k

Operating costs

This companyUSD 1.81kMedianUSD 201.81kAverageUSD 2.10m

Assets

This companyUSD 2.34kMedianUSD 118.27kAverageUSD 1.54m

Industry

Authorized Representatives

Zbigniew Majka – President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board is authorized to represent the company independently. If the management board consists of two or more persons, two members of the management board are authorized to represent the company acting jointly, provided that one of them must be the Vice-President for Financial Affairs, if appointed, or a member of the management board acting jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
ASI Platinum Alfa sp. z o.o. + limited partnership	50	$675.31	25%
Zbigniew Majkaage 52	150	$2,025.93	75%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-11-01.

PKO Bank Polski
25 1020 4391 0000 6702 0201 7051
PKO Bank Polski
70 1020 4391 0000 6002 0201 7069
PKO Bank Polski
72 1020 4391 0000 6902 0201 7077

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Nov 20, 2020	Aid for SME access to finance — aid for start-ups	$225.7K$225,653	Dyrektor Narodowego Centrum Badań i Rozwoju

Competitors

Name	Revenue	Website
ICN Polfa RzeszówS.A.	$85,044,250.03	icnpolfa.pl
Natur DayS.A.	$680,635.59	naturday.pl
Biotriosp. z o.o.	$453,662.22	biotrio.pl
Nature's Voicesp. z o.o.	$181,977.76	naturesvoice.eu
Pexon Polandsp. z o.o.	$122,615.96	pexon.pl
Bioresearch PharmaS.A.	$21,432.15	bioresearchpharma.com
Sanford Biotechsp. z o.o.	$2,586.64	sanfordbiotech.com
Cefeasp. z o.o.	$294.66	cefea.pl
Auxilius PharmaS.A.	$0.83	auxiliuspharma.com
Grupa FinepharmS.A.	–	finepharm.pl